# The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)

> **NCT02336555** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 35 (actual)

## Conditions studied

- Postherpetic Neuralgia

## Interventions

- **DRUG:** MK-8291
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02336555
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-12
- **Primary completion:** 2016-02-29
- **Final completion:** 2016-02-29
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336555, "The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02336555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*